MTVA MetaVia Inc.
MetaVia Inc. (MTVA) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.94 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.2% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology